Cells require tight regulation of the intracellular redox balance and consequently of reactive oxygen species for proper redox signaling and maintenance of metal (e.g., of iron and copper) homeostasis. In several diseases, including cancer, this balance is disturbed. Therefore, anticancer drugs targeting the redox systems, for example, glutathione and thioredoxin, have entered focus of interest. Anticancer metal complexes (platinum, gold, arsenic, ruthenium, rhodium, copper, vanadium, cobalt, manganese, gadolinium, and molybdenum) have been shown to strongly interact with or even disturb cellular redox homeostasis. In this context, especially the hypothesis of “activation by reduction” as well as the “hard and soft acids and bases” theory with respect to coordination of metal ions to cellular ligands represent important concepts to understand the molecular modes of action of anticancer metal drugs. The aim of this review is to highlight specific interactions of metal-based anticancer drugs with the cellular redox homeostasis and to explain this behavior by considering chemical properties of the respective anticancer metal complexes currently either in (pre)clinical development or in daily clinical routine in oncology. Antioxid. Redox Signal. 15, 1085–1127.
Abdel-WahabO, LevineRL. Metabolism and the leukemic stem cell. J Exp Med, 207:677–680. 2010.
2.
AguirreJD, Angeles-BozaAM, ChouaiA, PelloisJP, TurroC, DunbarKR. Live cell cytotoxicity studies: documentation of the interactions of antitumor active dirhodium compounds with nuclear DNA. J Am Chem Soc, 131:11353–11360. 2009.
3.
AhmadiR, UrigS, HartmannM, HelmkeBM, KoncarevicS, AllenbergerB, KienhoeferC, NeherM, SteinerHH, UnterbergA, Herold-MendeC, BeckerK. Antiglioma activity of 2,2′:6′,2"-terpyridineplatinum(II) complexes in a rat model—effects on cellular redox metabolism. Free Radic Biol Med, 40:763–778. 2006.
4.
AhnGO, BottingKJ, PattersonAV, WareDC, TercelM, WilsonWR. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem Pharmacol, 71:1683–1694. 2006.
5.
AhnGO, WareDC, DennyWA, WilsonWR. Optimization of the auxiliary ligand shell of Cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs. Radiat Res, 162:315–325. 2004.
6.
AirdRE, CummingsJ, RitchieAA, MuirM, MorrisRE, ChenH, SadlerPJ, JodrellDI. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer, 86:1652–1657. 2002.
7.
AlexandreJ, NiccoC, ChereauC, LaurentA, WeillB, GoldwasserF, BatteuxF. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst, 98:236–244. 2006.
8.
AltamuraC, SquittiR, PasqualettiP, GaudinoC, PalazzoP, TibuzziF, LupoiD, CortesiM, RossiniPM, VernieriF. Ceruloplasmin/Transferrin system is related to clinical status in acute stroke. Stroke, 40:1282–1288. 2009.
AndersonRF, DennyWA, WareDC, WilsonWR. Pulse radiolysis studies on the hypoxia-selective toxicity of a colbalt-mustard complex. Br J Cancer Suppl, 27:S48–S51. 1996.
11.
AnestalK, ArnerES. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem, 278:15966–15972. 2003.
12.
AntholineWE, TaketaF. Effects of 2-formylpyridine monothiosemicarbazonato copper II on red cell components. J Inorg Biochem, 20:69–78. 1984.
13.
AposhianHV, ZakharyanRA, AvramMD, Sampayo-ReyesA, WollenbergML. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol Appl Pharmacol, 198:327–335. 2004.
14.
ArionVB, ReisnerE, FremuthM, JakupecMA, KepplerBK, KukushkinVY, PombeiroAJL. Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of isomeric (1H-1,2,4-triazole)Ru(III) complexes. Inorg Chem, 42:6024–6031. 2003.
15.
ArnerES, HolmgrenA. The thioredoxin system in cancer. Semin Cancer Biol, 16:420–426. 2006.
16.
ArnerES, NakamuraH, SasadaT, YodoiJ, HolmgrenA, SpyrouG. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med, 31:1170–1178. 2001.
17.
ArredondoM, NunezMT. Iron and copper metabolism. Mol Aspects Med, 26:313–327. 2005.
BalamuruganK, SchaffnerW. Copper homeostasis in eukaryotes: teetering on a tightrope. Biochim Biophys Acta, 1763:737–746. 2006.
20.
BaldwinEL, BylJA, OsheroffN. Cobalt enhances DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells. Biochemistry, 43:728–735. 2004.
21.
BalesBC, PitieM, MeunierB, GreenbergMM. A minor groove binding copper-phenanthroline conjugate produces direct strand breaks via beta-elimination of 2-deoxyribonolactone. J Am Chem Soc, 124:9062–9063. 2002.
22.
BallatoriN, KranceSM, MarchanR, HammondCL. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol Aspects Med, 30:13–28. 2009.
23.
BardAJ, FaulknerLR. Electrochemical Methods Fundamentals and Applications. New York: John Wiley & Sons, 2001.
24.
BardAJ, ParsonsR, JordanJ. Standard Potentials in Aqueous Solution. New York: Dekker, 1985; 834.
25.
BarretteWCJr., JohnsonHWJr., SawyerDT. Voltammetric evaluation of the effective acidities (pKa') for Broensted acids in aprotic solvents. Anal Chem, 56:1890–1898. 1984.
26.
BasuS, MajumderS, ChatterjeeS, GangulyA, EfferthT, ChoudhuriSK. Detection and characterization of a glutathione conjugate of a novel copper complex. In Vivo, 23:401–408. 2009.
Batinic-HaberleI, SpasojevicI, TseH, TovmasyanA, RajicZ, St. ClairD, VujaskovicZ, DewhirstM, PiganelliJ. Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids, 2010[Epub ahead of print]DOI:10.1007/s00726-010-0636-6.
29.
BauerJA, LupicaJA, SchmidtH, MorrisonBH, HaneyRM, MasciRK, LeeRM, DidonatoJA, LindnerDJ. Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling. PLoS One, 2:e1313. 2007.
30.
BeckerK, Herold-MendeC, ParkJJ, LoweG, SchirmerRH. Human thioredoxin reductase is efficiently inhibited by (2,2′:6′,2′ ′-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J Med Chem, 44:2784–2792. 2001.
31.
BenciniA, FailliP, ValtancoliB, BaniD. Low molecular weight compounds with transition metals as free radical scavengers and novel therapeutic agents. Cardiovasc Hematol Agents Med Chem, 8:128–146. 2010.
BernhardtPV, SharpePC, IslamM, LovejoyDB, KalinowskiDS, RichardsonDR. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem, 52:407–415. 2009.
34.
BertolasoL, MartiniA, BindiniD, LanzoniI, ParmeggianiA, VitaliC, KalinecG, KalinecF, CapitaniS, PreviatiM. Apoptosis in the OC-k3 immortalized cell line treated with different agents. Audiology, 40:327–335. 2001.
35.
BeyersmannD, HartwigA. Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms. Arch Toxicol, 82:493–512. 2008.
BiaglowJE, MillerRA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther, 4:6–13. 2005.
38.
BinetF, ChiassonS, GirardD. Arsenic trioxide induces endoplasmic reticulum stress-related events in neutrophils. Int Immunopharmacol, 10:508–512. 2010.
39.
BishayeeA, WaghrayA, PatelMA, ChatterjeeM. Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence. Cancer Lett, 294:1–12. 2010.
40.
BlumO, HaiekA, CwikelD, DoriZ, MeadeTJ, GrayHB. Isolation of a myoglobin molten globule by selective cobalt(III)-induced unfolding. Proc Natl Acad Sci U S A, 95:6659–6662. 1998.
41.
BonnitchaPD, HallMD, UnderwoodCK, ForanGJ, ZhangM, BealePJ, HambleyTW. XANES investigation of the Co oxidation state in solution and in cancer cells treated with Co(III) complexes. J Inorg Biochem, 100:963–971. 2006.
42.
BoseRN, WeaverEL. A long-lived ascorbate radical in the platinum(II) catalysed reductions of platinum(IV) antitumor drugs. J Chem Soc Dalton Trans, 11:1797–1799. 1997.
43.
BowerJJ, LeonardSS, ChenF, ShiX. As(III) transcriptionally activates the gadd45a gene via the formation of H2O2. Free Radic Biol Med, 41:285–294. 2006.
44.
BowlingBD, DoudicanN, MangaP, OrlowSJ. Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer Chemother Pharmacol, 63:37–43. 2008.
45.
BrabecV, NovakovaO. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Updat, 9:111–122. 2006.
BrewerGJ, DickRD, GroverDK, LeClaireV, TsengM, WichaM, PientaK, RedmanBG, JahanT, SondakVK, StrawdermanM, LeCarpentierG, MerajverSD. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res, 6:1–10. 2000.
48.
Brigelius-FloheR, KippA. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta, 1790:1555–1568. 2009.
49.
BuettnerGR. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys, 300:535–543. 1993.
50.
BuettnerGR, JurkiewiczBA. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res, 145:532–541. 1996.
51.
ByrnesRW, AntholineWE, PeteringDH. Oxidation-reduction reactions in Ehrlich cells treated with copper-neocuproine. Free Radic Biol Med, 13:469–478. 1992.
52.
ByrnesRW, MohanM, AntholineWE, XuRX, PeteringDH. Oxidative stress induced by a copper-thiosemicarbazone complex. Biochemistry, 29:7046–7053. 1990.
53.
CanumallaAJ, Al-ZamilN, PhillipsM, IsabAA, ShawCF3rd. Redox and ligand exchange reactions of potential gold(I) and gold(III)-cyanide metabolites under biomimetic conditions. J Inorg Biochem, 85:67–76. 2001.
54.
CardeP, TimmermanR, MehtaMP, KoprowskiCD, FordJ, TishlerRB, MilesD, MillerRA, RenschlerMF. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol, 19:2074–2083. 2001.
55.
CarrJL, TingleMD, McKeageMJ. Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro. Cancer Chemother Pharmacol, 57:483–490. 2006.
56.
CascalesM, Martin-SanzP, CraciunescuDG, MayoI, AguilarA, Robles-ChillidaEM, CascalesC. Alterations in hepatic peroxidation mechanisms in thioacetamide-induced tumors in rats. Effect of a rhodium(III) complex. Carcinogenesis (London), 12:233–240. 1991.
57.
CasiniA, CinelluMA, MinghettiG, GabbianiC, CoronnelloM, MiniE, MessoriL. Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. J Med Chem, 49:5524–5531. 2006.
58.
CasiniA, GabbianiC, SorrentinoF, RigobelloMP, BindoliA, GeldbachTJ, MarroneA, ReN, HartingerCG, DysonPJ, MessoriL. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J Med Chem, 51:6773–6781. 2008.
59.
ChakrabortyA, GhoshR, RoyK, GhoshS, ChowdhuryP, ChatterjeeM. Vanadium: a modifier of drug-metabolizing enzyme patterns and its critical role in cellular proliferation in transplantable murine lymphoma. Oncology, 52:310–314. 1995.
60.
ChaneySG, CampbellSL, BassettE, WuY. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol, 53:3–11. 2005.
61.
ChaneySG, GibbonsGR, WyrickSD, PodhaskyP. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line. Cancer Res, 51:969–973. 1991.
62.
ChaneySG, WyrickS, TillGK. Invitro biotransformations of tetrachloro(D,L-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res, 50:4539–4545. 1990.
63.
ChatterjeeD, WardMS, ShepherdRE. Detection of N-3 and N-7-coordinated [RuII(edta)(5′-GMP)]4- complexes and the N-1 protonation equilibrium of the RuIII derivative. Inorg Chim Acta, 285:170–177. 1999.
64.
ChatterjeeS, MookerjeeA, BasuJM, ChakrabortyP, GangulyA, AdhikaryA, MukhopadhyayD, GanguliS, BanerjeeR, AshrafM, BiswasJ, DasPK, SaG, ChatterjeeM, DasT, ChoudhuriSK. A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells. PLoS One, 4:e7048. 2009.
65.
ChenD, MilacicV, FrezzaM, DouQP. Metal complexes, their cellular targets and potential for cancer therapy. Curr Pharm Des, 15:777–791. 2009.
66.
ChenGQ, ShiXG, TangW, XiongSM, ZhuJ, CaiX, HanZG, NiJH, ShiGY, JiaPM, LiuMM, HeKL, NiuC, MaJ, ZhangP, ZhangTD, PaulP, NaoeT, KitamuraK, MillerW, WaxmanS, WangZY, de TheH, ChenSJ, ChenZ. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 89:3345–3353. 1997.
67.
ChenHH, KuoMT. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs, 2010[Epub ahead of print]DOI:10.1155/2010/430939.
68.
ChenL, LeePF, RanfordJD, VittalJJ, WongSY. Reduction of the anti-cancer drug analogue cis,trans,cis[PtCl2(OCOCH3)(2)(NH3)(2)] by L-cysteine and L-methionine and its crystal structure. J Chem Soc Dalton Trans, 8:1209–1212. 1999.
69.
ChengY, ZakO, AisenP, HarrisonSC, WalzT. Structure of the human transferrin receptor-transferrin complex. Cell, 116:565–576. 2004.
70.
ChiaveriniN, De LeyM. Protective effect of metallothionein on oxidative stress-induced DNA damage. Free Radic Res, 44:605–613. 2010.
71.
ChibberR, StratfordIJ, O NeillP, SheldonPW, AhmedI, LeeB. The interaction between radiation and complexes of cis-Pt(II) and Rh(II): studies at the molecular and cellular level. Int J Radiat Biol, 48:513–524. 1985.
72.
ChikiraM, TomizawaY, FukitaD, SugizakiT, SugawaraN, YamazakiT, SasanoA, ShindoH, PalaniandavarM, AntholineWE. DNA-fiber EPR study of the orientation of Cu(II) complexes of 1,10-phenanthroline and its derivatives bound to DNA: mono(phenanthroline)-copper(II) and its ternary complexes with amino acids. J Inorg Biochem, 89:163–173. 2002.
73.
ChirinoYI, Pedraza-ChaverriJ. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol, 61:223–242. 2009.
ClarkeMJ, JansenB, MarxKA, KrugerR. Biochemical effects of binding pentaammineaquaruthenium(2+) to DNA and oxidation to [(NH3)5RuIII]n-DNA. Inorg Chim Acta, 124:13–28. 1986.
CorazzaA, HarveyI, SadlerPJ. 1H,13C-NMR and X-ray absorption studies of copper(I) glutathione complexes. Eur J Biochem, 236:697–705. 1996.
81.
CortiA, CasiniAF, PompellaA. Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. Arch Biochem Biophys, 500:107–115. 2010.
82.
CoxAG, WinterbournCC, HamptonMB. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem J, 425:313–325. 2010.
83.
CransDC, ZhangB, GaidamauskasE, KeramidasAD, WillskyGR, RobertsCR. Is vanadate reduced by thiols under biological conditions? changing the redox potential of V(V)/V(IV) by complexation in aqueous solution. Inorg Chem, 49:4245–4256. 2010.
84.
CullenKJ, NewkirkKA, SchumakerLM, AldosariN, RoneJD, HaddadBR. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res, 63:8097–8102. 2003.
85.
CustodioJB, CardosoCM, SantosMS, AlmeidaLM, VicenteJA, FernandesMA. Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: prevention by thiol group protecting agents. Toxicology, 259:18–24. 2009.
86.
D'CruzOJ, UckunFM. Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity. Expert Opin Investig Drugs, 11:1829–1836. 2002.
87.
DaiJ, WeinbergRS, WaxmanS, JingY. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 93:268–277. 1999.
88.
Dalle-DonneI, RossiR, ColomboG, GiustariniD, MilzaniA. Protein S-glutathionylation: a regulatory device from bacteria to humans. Trends Biochem Sci, 34:85–96. 2009.
89.
DennyWA. Prodrug strategies in cancer therapy. Eur J Med Chem, 36:577–595. 2001.
90.
DennyWA. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Future Oncol, 6:419–428. 2010.
91.
DesoizeB. Metals and metal compounds in cancer treatment. Anticancer Res, 24:1529–1544. 2004.
92.
DiazZ, ColomboM, MannKK, SuH, SmithKN, BohleDS, SchipperHM, MillerWHJr.Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood, 105:1237–1245. 2005.
93.
DildaPJ, HoggPJ. Arsenical-based cancer drugs. Cancer Treat Rev, 33:542–564. 2007.
94.
DildaPJ, RamsayEE, CortiA, PompellaA, HoggPJ. Metabolism of the tumor angiogenesis inhibitor 4-(N-(S-Glutathionylacetyl)amino)phenylarsonous acid. J Biol Chem, 283:35428–35434. 2008.
95.
DittrichC, ScheulenME, JaehdeU, KynastB, GneistM, RichlyH, SchaadS, ArionVB, KepplerBK. Phase I and pharmacokinetic study of sodium trans- [tetrachlorobis(1H-indazole)ruthenate(III)]/indazolehydrochloride (1:1.1) (FFC14A, KP1019) in patients with solid tumors–a study of the CESAR Central European Society for Anticancer Drug Research—EWIV. Proceedings of the American Association for Cancer Research, 46:P472. 2005.
96.
DjordjevicC, WamplerGL. Antitumor activity and toxicity of peroxo heteroligand vanadates(V) in relation to biochemistry of vanadium. J Inorg Biochem, 25:51–55. 1985.
97.
DonAS, KiskerO, DildaP, DonoghueN, ZhaoX, DecollogneS, CreightonB, FlynnE, FolkmanJ, HoggPJ. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell, 3:497–509. 2003.
98.
dos SantosNA, MartinsNM, CurtiC, Pires Bianchi MdeL, dos SantosAC. Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats. Chem Biol Interact, 170:177–186. 2007.
EjimaK, LayneMD, CarvajalIM, NanriH, IthB, YetSF, PerrellaMA. Modulation of the thioredoxin system during inflammatory responses and its effect on heme oxygenase-1 expression. Antioxid Redox Signal, 4:569–575. 2002.
103.
El-NaggarMM, El-WaseefAM, El-HalafawyKM, El-SayedIH. Antitumor activities of vanadium(IV), manganese(IV), iron(III), cobalt(II) and copper(II) complexes of 2-methylaminopyridine. Cancer Lett, 133:71–76. 1998.
104.
ElderRC, ZhaoZ, ZhangY, DorseyJG, HessEV, TeppermanK. Dicyanogold (I) is a common human metabolite of different gold drugs. J Rheumatol, 20:268–272. 1993.
105.
EllisLT, ErHM, HambleyTW. The influence of the axial ligands of a series of platinum(IV) anticancer complexes on their reduction to platinum(II) and reaction with DNA. Aust J Chem, 48:793–806. 1995.
106.
EvangelouAM. Vanadium in cancer treatment. Crit Rev Oncol Hematol, 42:249–265. 2002.
107.
EvensAM, TallmanMS, GartenhausRB. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res, 28:891–900. 2004.
108.
FaureR, VincentM, DufourM, ShaverA, PosnerBI. Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line. J Cell Biochem, 59:389–401. 1995.
109.
FentonHJH. On a new reaction of tartaric acid. Chem News, 33:190. 1876.
110.
Ferrer-SuetaG, Batinic-HaberleI, SpasojevicI, FridovichI, RadiR. Catalytic scavenging of peroxynitrite by isomeric Mn(III) N-methylpyridylporphyrins in the presence of reductants. Chem Res Toxicol, 12:442–449. 1999.
111.
FinchRA, LiuMC, CoryAH, CoryJG, SartorelliAC. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul, 39:3–12. 1999.
112.
FokkemaE, GroenHJ, HelderMN, de VriesEG, MeijerC. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol, 63:1989–1996. 2002.
113.
FormanHJ, ZhangH, RinnaA. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med, 30:1–12. 2009.
114.
FradeRFM, CandeiasNR, DuarteCMM, AndréV, Teresa DuarteM, GoisPMP, AfonsoCAM. New dirhodium complex with activity towards colorectal cancer. Bioorg Med Chem Lett, 20:3413–3415. 2010.
115.
FrancoR, CidlowskiJA. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ, 16:1303–1314. 2009.
116.
FrascaDR, ClarkeMJ. Alterations in the binding of [Cl(NH3)5RuIII]2+to DNA by glutathione: reduction, autoxidation, coordination, and decomposition. J Am Chem Soc, 121:8523–8532. 1999.
117.
FriesJF, BlochD, SpitzP, MitchellDM. Cancer in rheumatoid arthritis: a prospective long-term study of mortality. Am J Med, 78:56–59. 1985.
118.
FruhaufS, ZellerWJ. In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and -resistant rat ovarian tumors. Cancer Chemother Pharmacol, 27:301–307. 1991.
119.
FuPKL, BradleyPM, TurroC. DNA Cleavage by Photogenerated Rh2(O2CCH3)4(H2O)2+Inorg Chem, 40:2476–2477. 2001.
120.
GalanskiM, JakupecMA, KepplerBK. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem, 12:2075–2094. 2005.
121.
GallagherJ, ChenCH, PanCQ, PerrinDM, ChoYM, SigmanDS. Optimizing the targeted chemical nuclease activity of 1,10-phenanthroline-copper by ligand modification. Bioconjug Chem, 7:413–420. 1996.
122.
GandinV, FernandesAP, RigobelloMP, DaniB, SorrentinoF, TisatoF, BjornstedtM, BindoliA, SturaroA, RellaR, MarzanoC. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem Pharmacol, 79:90–101. 2010.
123.
GanycD, TalbotS, KonateF, JacksonS, SchanenB, CullenW, SelfWT. Impact of trivalent arsenicals on selenoprotein synthesis. Environ Health Perspect, 115:346–353. 2007.
124.
GibsonD. The mechanism of action of platinum anticancer agents—what do we really know about it?Dalton Trans, 48:10681–10689. 2009.
125.
GiommarelliC, CortiA, SupinoR, FaviniE, PaolicchiA, PompellaA, ZuninoF. Gamma-glutamyltransferase-dependent resistance to arsenic trioxide in melanoma cells and cellular sensitization by ascorbic acid. Free Radic Biol Med, 46:1516–1526. 2009.
126.
GlicksteinH, ElRB, ShvartsmanM, CabantchikZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood, 106:3242–3250. 2005.
GregusZ, NemetiB. The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase works as an arsenate reductase in human red blood cells and rat liver cytosol. Toxicol Sci, 85:859–869. 2005.
133.
GuptaY, KohliDV, JainSK. Vitamin B12-mediated transport: a potential tool for tumor targeting of antineoplastic drugs and imaging agents. Crit Rev Ther Drug Carrier Syst, 25:347–379. 2008.
134.
GupteA, MumperRJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev, 35:32–46. 2009.
135.
GustR, OttI, PosseltD, SommerK. Development of cobalt(3,4-diarylsalen) complexes as tumor therapeutics. J Med Chem, 47:5837–5846. 2004.
136.
HaberF, WeissJ. The catalytic decomposition of hydrogen peroxide by iron salts. Proc R Soc Lond Ser A, 147:332–351. 1934.
137.
HallMD, AmjadiS, ZhangM, BealePJ, HambleyTW. The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines. J Inorg Biochem, 98:1614–1624. 2004.
HallMD, MellorHR, CallaghanR, HambleyTW. Basis for design and development of platinum(IV) anticancer complexes. J Med Chem, 50:3403–3411. 2007.
140.
HalliwellB, GutteridgeJMC. Free Radicals in Biology and Medicine. New York: Oxford University Press, 1988; 374.
141.
HambleyTW, BattleAR, DeaconGB, LawrenzET, FallonGD, GatehouseBM, WebsterLK, RainoneS. Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness. J Inorg Biochem, 77:3–12. 1999.
142.
HanYH, KimSZ, KimSH, ParkWH. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett, 270:40–55. 2008.
143.
HancockCN, StockwinLH, HanB, DivelbissRD, JunJH, MalhotraSV, HollingsheadMG, NewtonDL. A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo. Free Radic Biol Med, 50:110–121. 2011.
144.
HaniganMH, DevarajanP. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther, 1:47–61. 2003.
145.
HannaPM, KadiiskaMB, MasonRP. Oxygen-derived free radical and active oxygen complex formation from cobalt(II) chelates in vitro. Chem Res Toxicol, 5:109–115. 1992.
146.
HannemannJ, BaumannK. Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers. Toxicology, 51:119–132. 1988.
147.
HardingMM, MokdsiG. Antitumour metallocenes: structure-activity studies and interactions with biomolecules. Curr Med Chem, 7:1289–1303. 2000.
HartingerCG, Zorbas-SeifriedS, JakupecMA, KynastB, ZorbasH, KepplerBK. From bench to bedside—preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)J Inorg Biochem, 100:891–904. 2006.
150.
HayakawaT, KobayashiY, CuiX, HiranoS. A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch Toxicol, 79:183–191. 2005.
151.
HayesJD, McMahonM, ChowdhryS, Dinkova-KostovaAT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal, 13:1713–1748. 2010.
152.
HealyJ, TiptonK. Ceruloplasmin and what it might do. J Neural Transm, 114:777–781. 2007.
153.
HedstromE, ErikssonS, Zawacka-PankauJ, ArnerES, SelivanovaG. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle, 8:3576–3583. 2009.
154.
HeffeterP, BockK, AtilB, Reza HodaMA, KornerW, BartelC, JungwirthU, KepplerBK, MickscheM, BergerW, KoellenspergerG. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J Biol Inorg Chem, 15:737–748. 2010.
155.
HeffeterP, JungwirthU, JakupecM, HartingerC, GalanskiM, ElblingL, MickscheM, KepplerB, BergerW. Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat, 11:1–16. 2008.
156.
HeffeterP, Popovic-BijelicA, SaikoP, DornetshuberR, JungwirthU, VoevodskayaN, BiglinoD, JakupecMA, ElblingL, MickscheM, SzekeresT, KepplerBK, GraslundA, BergerW. Ribonucleotide reductase as one important target of [tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772)Curr Cancer Drug Targets, 9:595–607. 2009.
157.
HellbergV, WallinI, ErikssonS, HernlundE, JerremalmE, BerndtssonM, EksborgS, ArnerES, ShoshanM, EhrssonH, LaurellG. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst, 101:37–47. 2009.
158.
HentzeMW, MuckenthalerMU, AndrewsNC. Balancing acts: molecular control of mammalian iron metabolism. Cell, 117:285–297. 2004.
159.
HokeGD, McCabeFL, FaucetteLF, BartusJO, SungCM, JensenBD, HeysJR, RushGF, AlbertsDW, JohnsonRKet al.In vivo development and in vitro characterization of a subclone of murine P388 leukemia resistant to bis(diphenylphosphine)ethane. Mol Pharmacol, 39:90–97. 1991.
160.
HokeGD, RushGF, BossardGF, McArdleJV, JensenBD, MirabelliCK. Mechanism of alterations in isolated rat liver mitochondrial function induced by gold complexes of bidentate phosphines. J Biol Chem, 263:11203–11210. 1988.
161.
HokeGD, RushGF, MirabelliCK. The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes. III. Chlorotriethylphosphine gold(I)-induced alterations in isolated rat liver mitochondrial function. Toxicol Appl Pharmacol, 99:50–60. 1989.
162.
HollemanAF, WibergE, WibergN. Inorganic Chemistry. Berlin: de Gryter, 2001; 1924.
163.
HouMH, LuWJ, HuangCY, FanRJ, YuannJM. Effects of polyamines on the DNA-reactive properties of dimeric mithramycin complexed with cobalt(II): implications for anticancer therapy. Biochemistry, 48:4691–4698. 2009.
HowardRA, SpringTG, BearJL. The interaction of rhodium(II) carboxylates with enzymes. Cancer Res, 36:4402–4405. 1976.
166.
HowellSB, SafaeiR, LarsonCA, SailorMJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol, 77:887–894. 2010.
167.
HuJ, LiuYF, WuCF, XuF, ShenZX, ZhuYM, LiJM, TangW, ZhaoWL, WuW, SunHP, ChenQS, ChenB, ZhouGB, ZelentA, WaxmanS, WangZY, ChenSJ, ChenZ. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 106:3342–3347. 2009.
168.
HuyerG, LiuS, KellyJ, MoffatJ, PayetteP, KennedyB, TsaprailisG, GresserMJ, RamachandranC. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem, 272:843–851. 1997.
169.
IshidaS, McCormickF, Smith-McCuneK, HanahanD. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell, 17:574–583. 2010.
170.
ItohK, WakabayashiN, KatohY, IshiiT, IgarashiK, EngelJD, YamamotoM. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev, 13:76–86. 1999.
171.
JakimowiczP, OstropolskaL, PruchnikFP. Interaction of [Rh2(O2CCH3)4(H2O)2] and [Rh2(O2CCH(OH)Ph)2(phen)2(H2O)2](O2CCH(OH)Ph)2 with sulfhydryl compounds and ceruloplasmin. Met-Based Drugs, 7:201–209. 2000.
172.
JakupecMA, GalanskiM, KepplerBK. Tumour-inhibiting platinum complexes—state of the art and future perspectives. Rev Physiol Biochem Pharmacol, 146:1–54. 2003.
173.
JakupecMA, ReisnerE, EichingerA, PongratzM, ArionVB, GalanskiM, HartingerCG, KepplerBK. Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. J Med Chem, 48:2831–2837. 2005.
174.
JaramilloMC, FryeJB, CrapoJD, BriehlMM, TomeME. Increased manganese superoxide dismutase expression or treatment with manganese porphyrin potentiates dexamethasone-induced apoptosis in lymphoma cells. Cancer Res, 69:5450–5457. 2009.
175.
JaspersI, SametJM, ErzurumS, ReedW. Vanadium-induced kappaB-dependent transcription depends upon peroxide-induced activation of the p38 mitogen-activated protein kinase. Am J Respir Cell Mol Biol, 23:95–102. 2000.
176.
JennetteKW, LippardSJ, VassiliadesGA, BauerWR. Metallointercalation reagents. 2-hydroxyethanethiolato(2,2′,2′-terpyridine)-platinum(II) monocation binds strongly to DNA by intercalation. Proc Natl Acad Sci U S A, 71:3839–3843. 1974.
JiangH, MaY, ChenX, PanS, SunB, KrissansenGW, SunX. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cancer Sci, 101:975–983. 2010.
179.
JiangM, DongZ. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther, 327:300–307. 2008.
JungM, KerrDE, SenterPD. Bioorganometallic chemistry—synthesis and antitumor activity of cobalt carbonyl complexes. Arch Pharm (Weinheim), 330:173–176. 1997.
182.
KadishiKM, DasK, HowardR, DennisA, BearJL. 264- Redox Reactions and Antitumor Activity of Tetra-[mu]-Carboxylatodirhodium(II)Bioelectrochem Bioenerg, 5:741–753. 1978.
183.
KakhlonO, CabantchikZI. The labile iron pool: characterization, measurement, and participation in cellular processes(1)Free Radic Biol Med, 33:1037–1046. 2002.
184.
KamalakannanP, VenkappayyaD. Synthesis and characterization of cobalt and nickel chelates of 5-dimethylaminomethyl-2-thiouracil and their evaluation as antimicrobial and anticancer agents. J Inorg Biochem, 90:22–37. 2002.
185.
KapitzaS, JakupecMA, UhlM, KepplerBK, MarianB. The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett, 226:115–121. 2005.
186.
KapitzaS, PongratzM, JakupecMA, HeffeterP, BergerW, LackingerL, KepplerBK, MarianB. Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. J Cancer Res Clin Oncol, 131:101–110. 2005.
187.
KasprzakKS, ZastawnyTH, NorthSL, RiggsCW, DiwanBA, RiceJM, DizdarogluM. Oxidative DNA base damage in renal, hepatic, and pulmonary chromatin of rats after intraperitoneal injection of cobalt(II) acetate. Chem Res Toxicol, 7:329–35. 1994.
188.
KatsarosN, AnagnostopoulouA. Rhodium and its compounds as potential agents in cancer treatment. Crit Rev Oncol Hematol, 42:297–308. 2002.
189.
KellandL. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 7:573–584. 2007.
190.
KhanMF, OhnoY, TakanakaA. Effect of tetrakis-mu-3,5-diisopropylsalicylatodiaquodicopper(II) on the status of reduced glutathione in freshly isolated hepatocytes. Arch Toxicol, 66:587–591. 1992.
191.
KidoY, KhokharAR, SiddikZH. Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells. Biochem Pharmacol, 47:1635–1642. 1994.
192.
KidoY, KhokharAR, YoshidaM, ThaiGW, SiddikZH. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice. Drug Metab Dispos, 22:312–317. 1994.
193.
KimH, SonHY, BaileySM, LeeJ. Deletion of hepatic Ctr1 reveals its function in copper acquisition and compensatory mechanisms for copper homeostasis. Am J Physiol Gastrointest Liver Physiol, 296:G356–G364. 2009.
194.
KimI, XuW, ReedJC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov, 7:1013–1030. 2008.
195.
KimNH, LeeMY, ParkSJ, ChoiJS, OhMK, KimIS. Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology, 122:607–614. 2007.
196.
KimNH, OhMK, ParkHJ, KimIS. Auranofin, a gold(I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation. J Pharmacol Sci, 113:246–254. 2010.
197.
KirlinWG, CaiJ, ThompsonSA, DiazD, KavanaghTJ, JonesDP. Glutathione redox potential in response to differentiation and enzyme inducers. Free Radical Biol Med, 27:1208–1218. 1999.
198.
KnoxRJ, FriedlosF, LydallDA, RobertsJJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res, 46:1972–1979. 1986.
199.
KolbergM, StrandKR, GraffP, AnderssonKK. Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta, 1699:1–34. 2004.
200.
KoperaE, SchwerdtleT, HartwigA, BalW. Co(II) and Cd(II) substitute for Zn(II) in the zinc finger derived from the DNA repair protein XPA, demonstrating a variety of potential mechanisms of toxicity. Chem Res Toxicol, 17:1452–1458. 2004.
201.
Kopf-MaierP, KrahlD. Tumor inhibition by metallocenes: ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy. Chem Biol Interact, 44:317–328. 1983.
202.
KostovaI. Gold coordination complexes as anticancer agents. Anticancer Agents Med Chem, 6:19–32. 2006.
203.
KostovaI. Titanium and vanadium complexes as anticancer agents. Anticancer Agents Med Chem, 9:827–842. 2009.
204.
KowolCR, TrondlR, HeffeterP, ArionVB, JakupecMA, RollerA, GalanskiM, BergerW, KepplerBK. Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. J Med Chem, 52:5032–5043. 2009.
205.
KruszewskiM. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res Fundam Mol Mech Mutagen, 531:81–92. 2003.
206.
KuwabaraM, YoonC, GoyneT, ThederahnT, SigmanDS. Nuclease activity of 1,10-phenanthroline-copper ion: reaction with CGCGAATTCGCG and its complexes with netropsin and EcoRI. Biochemistry, 25:7401–7408. 1986.
207.
LaibJE, ShawCF3rd, PeteringDH, EidsnessMK, ElderRC, GarveyJS. Formation and characterization of aurothioneins: Au,Zn,Cd-thionein, Au,Cd-thionein, and (thiomalato-Au)chi-thionein. Biochemistry, 24:1977–1986. 1985.
208.
LaurentA, NiccoC, ChereauC, GoulvestreC, AlexandreJ, AlvesA, LevyE, GoldwasserF, PanisY, SoubraneO, WeillB, BatteuxF. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res, 65:948–956. 2005.
209.
LeeMT, AhmedT, HaddadR, FriedmanME. Inhibition of several enzymes by gold compounds. II. Beta-glucuronidase, acid phosphatase and L-malate dehydrogenase by sodium thiomalatoraurate (I), sodium thiosulfatoaurate (I) and thioglucosoaurate (I)J Enzyme Inhib, 3:35–47. 1989.
210.
LemmaK, BerglundJ, FarrellN, EldingLI. Kinetics and mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione. J Biol Inorg Chem, 5:300–306. 2000.
211.
LemmaK, HouseDA, RettaN, EldingLI. Kinetics and mechanism for reduction of halo- and haloam(m)ine platinum(IV) complexes by L-ascorbate. Inorganica Chimica Acta, 331:98–108. 2002.
212.
LemmaK, SargesonAM, EldingLI. Kinetics and mechanism for reduction of oral anticancer platinum(IV) dicarboxylate compounds by L-ascorbate ions. J Chem Society-Dalton Transactions, 7:1167–1172. 2000.
213.
LeverABP. Electrochemical parametrization of metal complex redox potentials, using the ruthenium(III)/ruthenium(II) couple to generate a ligand electrochemical series. Inorg Chem, 29:1271–1285. 1990.
214.
LiH, QianZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev, 22:225–250. 2002.
215.
LiH, SunH, QianZM. The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol Sci, 23:206–209. 2002.
LiY, SchellhornHE. New developments and novel therapeutic perspectives for vitamin C. J Nutr, 137:2171–2184. 2007.
218.
LideDR. CRC Handbook of Chemistry and Physics, 83rd2002; 2664.
219.
LinS, Del RazoLM, StybloM, WangC, CullenWR, ThomasDJ. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol, 14:305–311. 2001.
220.
LiochevSI. The mechanism of "Fenton-like" reactions and their importance for biological systems. A biologist's view. Met Ions Biol Syst, 36:1–39. 1999.
221.
LiuY, FiskumG, SchubertD. Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem, 80:780–787. 2002.
222.
LiuZQ. Chemical methods to evaluate antioxidant ability. Chem Rev, 110:5675–5691. 2010.
223.
LoYC, KoTP, SuWC, SuTL, WangAH. Terpyridine-platinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1. J Inorg Biochem, 103:1082–1092. 2009.
224.
LoweG, DrozAS, VilaivanT, WeaverGW, ParkJJ, PrattJM, TweedaleL, KellandLR. Cytotoxicity of 2,2′:6′,2′ '-terpyridineplatinum(II) complexes against human ovarian carcinoma. J Med Chem, 42:3167–3174. 1999.
225.
LuJ, ChewEH, HolmgrenA. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A, 104:12288–12293. 2007.
226.
LuoS, LevineRL. Methionine in proteins defends against oxidative stress. Faseb J, 23:464–72. 2009.
227.
MacKenzieEL, IwasakiK, TsujiY. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal, 10:997–1030. 2008.
228.
MagdaD, MillerRA. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol, 16:466–476. 2006.
229.
MagheriniF, ModestiA, BiniL, PugliaM, LandiniI, NobiliS, MiniE, CinelluMA, GabbianiC, MessoriL. Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. J Biol Inorg Chem, 15:573–582. 2009.
230.
MajumderS, DuttaP, MookerjeeA, ChoudhuriSK. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Chem Biol Interact, 159:90–103. 2006.
231.
MajumderS, PandaGS, Kumar ChoudhuriS. Synthesis, characterization and biological properties of a novel copper complex. Eur J Med Chem, 38:893–898. 2003.
232.
MalhotraJD, KaufmanRJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword?Antioxid Redox Signal, 9:2277–2293. 2007.
MandlJ, SzarkaA, BanhegyiG. Vitamin C: update on physiology and pharmacology. Br J Pharmacol, 157:1097–1110. 2009.
235.
MannKK, WallnerB, LossosIS, MillerWHJr.Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs, 18:1727–1734. 2009.
236.
MarconG, CarottiS, CoronnelloM, MessoriL, MiniE, OrioliP, MazzeiT, CinelluMA, MinghettiG. Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties. J Med Chem, 45:1672–1677. 2002.
237.
MarshallLE, GrahamDR, ReichKA, SigmanDS. Cleavage of deoxyribonucleic acid by the 1,10-phenanthroline-cuprous complex. Hydrogen peroxide requirement and primary and secondary structure specificity. Biochemistry, 20:244–250. 1981.
238.
MartinsNM, SantosNA, CurtiC, BianchiML, SantosAC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol, 28:337–344. 2008.
239.
MasudaH, TanakaT, TakahamaU. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun, 203:1175–1180. 1994.
240.
MatsuiM, OshimaM, OshimaH, TakakuK, MaruyamaT, YodoiJ, TaketoMM. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol, 178:179–185. 1996.
241.
MatulisSM, MoralesAA, YehiayanL, CroutchC, GutmanD, CaiY, LeeKP, BoiseLH. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther, 8:1197–1206. 2009.
242.
McCannM, GeraghtyM, DevereuxM, O'SheaD, MasonJ, O'SullivanL. Insights into the mode of action of the anti-Candida activity of 1,10-phenanthroline and its metal chelates. Met Based Drugs, 7:185–193. 2000.
243.
McCoubreyA, LathamHC, CookPR, RodgerA, LoweG. 4-Picoline-2,2′:6′,2"-terpyridine-platinum(II)—a potent intercalator of DNA. FEBS Lett, 380:73–78. 1996.
244.
MediciV, SturnioloGC. Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications. IDrugs, 11:592–606. 2008.
245.
MeijerC, MulderNH, Timmer-BosschaH, SluiterWJ, MeersmaGJ, de VriesEG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res, 52:6885–6889. 1992.
246.
MellishKJ, KellandLR, HarrapKR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer, 68:240–250. 1993.
247.
MeyersCA, SmithJA, BezjakA, MehtaMP, LiebmannJ, IllidgeT, KunklerI, CaudrelierJM, EisenbergPD, MeerwaldtJ, SiemersR, CarrieC, GasparLE, CurranW, PhanSC, MillerRA, RenschlerMF. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol, 22:157–165. 2004.
248.
MiaoL, St ClairDK. Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med, 47:344–356. 2009.
249.
MieyalJJ, GalloglyMM, QanungoS, SabensEA, SheltonMD. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal, 10:1941–1988. 2008.
250.
MilacicV, DouQP. The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. Coord Chem Rev, 253:1649–1660. 2009.
251.
MilanoG, CaldaniC, KhaterR, LaunayJM, SoummerAM, NamerM, SchneiderM. Time- and dose-dependent inhibition of erythrocyte glutathione peroxidase by cisplatin. Biochem Pharmacol, 37:981–982. 1988.
252.
MilbankJB, StevensonRJ, WareDC, ChangJY, TercelM, AhnGO, WilsonWR, DennyWA. Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihy dro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins. J Med Chem, 52:6822–6834. 2009.
253.
MistryP, LeeC, McBrienDC. Intracellular metabolites of cisplatin in the rat kidney. Cancer Chemother Pharmacol, 24:73–79. 1989.
254.
MookerjeeA, BasuJM, MajumderS, ChatterjeeS, PandaGS, DuttaP, PalS, MukherjeeP, EfferthT, RoyS, ChoudhuriSK. A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo. BMC Cancer, 6:267. 2006.
255.
MoralesAA, GutmanD, CejasPJ, LeeKP, BoiseLH. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J Biol Chem, 284:12886–12895. 2009.
256.
MorbidelliL, DonniniS, FilippiS, MessoriL, PiccioliF, OrioliP, SavaG, ZicheM. Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. Br J Cancer, 88:1484–1491. 2003.
257.
MorinvilleA, MaysingerD, ShaverA. From Vanadis to Atropos: vanadium compounds as pharmacological tools in cell death signalling. Trends Pharmacol Sci, 19:452–460. 1998.
258.
MoriyaM, HoYH, GranaA, NguyenL, AlvarezA, JamilR, AcklandML, MichalczykA, HamerP, RamosD, KimS, MercerJF, LinderMC. Copper is taken up efficiently from albumin and alpha2-macroglobulin by cultured human cells by more than one mechanism. Am J Physiol Cell Physiol, 295:C708–C721. 2008.
259.
MostertV, HillKE, FerrisCD, BurkRF. Selective induction of liver parenchymal cell heme oxygenase-1 in selenium-deficient rats. Biol Chem, 384:681–687. 2003.
260.
MukherjeeB, PatraB, MahapatraS, BanerjeeP, TiwariA, ChatterjeeM. Vanadium—an element of atypical biological significance. Toxicol Lett, 150:135–143. 2004.
261.
MuraP, CamalliM, BindoliA, SorrentinoF, CasiniA, GabbianiC, CorsiniM, ZanelloP, RigobelloMP, MessoriL. Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound. J Med Chem, 50:5871–5874. 2007.
262.
NaHK, SurhYJ. Transcriptional regulation via cysteine thiol modification: a novel molecular strategy for chemoprevention and cytoprotection. Mol Carcinog, 45:368–380. 2006.
263.
NagaharaN. Intermolecular disulfide bond to modulate protein function as a redox-sensing switch. Amino Acids, 2010[Epub ahead of print]DOI:10.1007/s00726-010-0508-4.
264.
NarasimhanJ, AntholineWE, ChitambarCR, PeteringDH. Inhibition of iron uptake in HL60 cells by 2-formylpyridine monothiosemicarbazonato Cu(II)Arch Biochem Biophys, 289:393–398. 1991.
265.
NauraAS, KallaNR, SharmaRP, SharmaR. Anticarcinogenic effects of hexaamminecobalt(III) chloride in mice initiated with diethylnitrosamine. Biol Trace Elem Res, 119:147–165. 2007.
266.
NauraAS, SharmaR. Toxic effects of hexaammine cobalt(III) chloride on liver and kidney in mice: implication of oxidative stress. Drug Chem Toxicol, 32:293–299. 2009.
267.
NemirovskiA, KashermanY, TzarafY, GibsonD. Reduction of cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by aqueous extracts of cancer cells. J Med Chem, 50:5554–5556. 2007.
268.
NemirovskiA, VinogradI, TakrouriK, MijovilovichA, RompelA, GibsonD. New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs. Chem Commun (Camb), 46:1842–1844. 2010.
269.
NeumannCA, CaoJ, ManevichY. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle, 8:4072–4078. 2009.
270.
NeumannCA, FangQ. Are peroxiredoxins tumor suppressors?Curr Opin Pharmacol, 7:375–380. 2007.
271.
NicolisI, CurisE, DeschampsP, BenazethS. Arsenite medicinal use, metabolism, pharmacokinetics and monitoring in human hair. Biochimie, 91:1260–1267. 2009.
272.
NobiliS, MiniE, LandiniI, GabbianiC, CasiniA, MessoriL. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med Res Rev, 30:550–580. 2009.
273.
NocentiniG, BarziA. The 2,2′-bipyridyl-6-carbothioamide copper(II) complex differs from the iron(II) complex in its biochemical effects in tumor cells, suggesting possible differences in the mechanism leading to cytotoxicity. Biochem Pharmacol, 52:65–71. 1996.
274.
NocentiniG, BarziA. Antitumor activity of 2,2′-bipyridyl-6-carbothioamide: a ribonucleotide reductase inhibitor. Gen Pharmacol, 29:701–706. 1997.
275.
NonnL, WilliamsRR, EricksonRP, PowisG. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol, 23:916–922. 2003.
OtikoG, RaziMT, SadlerPJ, IsabAA, RabensteinDL. A 1H nmr study of the interaction of aurothiomalate (“Myocrisin”) with human red blood cells in vitro. J Inorg Biochem, 19:227–235. 1983.
285.
OttI, GustR. Non platinum metal complexes as anti-cancer drugs. Arch Pharm (Weinheim), 340:117–126. 2007.
286.
OttI, SchmidtK, KircherB, SchumacherP, WiglendaT, GustR. Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action. J Med Chem, 48:622–629. 2005.
287.
PaineA, Eiz-VesperB, BlasczykR, ImmenschuhS. Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol, 80:1895–1903. 2010.
288.
PalmiterRD. Protection against zinc toxicity by metallothionein and zinc transporter 1. Proc Natl Acad Sci U S A, 101:4918–4923. 2004.
289.
PapanikolaouG, PantopoulosK. Iron metabolism and toxicity. Toxicol Appl Pharmacol, 202:199–211. 2005.
290.
PassHI, BrewerGJ, DickR, CarboneM, MerajverS. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg, 86:383–389discussion 3902008.
291.
PastoreA, FedericiG, BertiniE, PiemonteF. Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta, 333:19–39. 2003.
292.
PaulMK, KumarR, MukhopadhyayAK. Dithiothreitol abrogates the effect of arsenic trioxide on normal rat liver mitochondria and human hepatocellular carcinoma cells. Toxicol Appl Pharmacol, 226:140–152. 2008.
293.
PavlishchukVV, AddisonAW. Conversion constants for redox potentials measured versus different reference electrodes in acetonitrile solutions at 25 DegC. Inorg Chim Acta, 298:97–102. 2000.
294.
PearsonRG. Hard and soft acids and bases. J Am Chem Soc, 85:3533–3539. 1963.
295.
PedersenMO, LarsenA, StoltenbergM, PenkowaM. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem, 44:29–64. 2009.
296.
PendyalaL, CowensJW, ChhedaGB, DuttaSP, CreavenPJ. Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans. Cancer Res, 48:3533–3536. 1988.
297.
PendyalaL, CreavenPJ, PerezR, ZdanowiczJR, RaghavanD. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother Pharmacol, 36:271–278. 1995.
298.
PetrickJS, Ayala-FierroF, CullenWR, CarterDE, Vasken AposhianH. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol, 163:203–207. 2000.
299.
PetzoldH, XuJ, SadlerPJ. Metal and ligand control of sulfenate reactivity: arene ruthenium thiolato-mono-S-oxides. Angewandte Chem Int Ed Engl, 47:3008–3011. 2008.
300.
PiccioliF, SabatiniS, MessoriL, OrioliP, HartingerCG, KepplerBK. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins. J Inorg Biochem, 98:1135–1142. 2004.
301.
PizarroAM, SadlerPJ. Unusual DNA binding modes for metal anticancer complexes. Biochimie, 91:1198–1211. 2009.
302.
PopeLM, ReichKA, GrahamDR, SigmanDS. Products of DNA cleavage by the 1,10-phenanthroline-copper complex. Inhibitors of Escherichia coli DNA polymerase I. J Biol Chem, 257:12121–12128. 1982.
303.
PorterJB, RafiqueR, SrichairatanakoolS, DavisBA, ShahFT, HairT, EvansP. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Ann N Y Acad Sci, 1054:155–168. 2005.
304.
QianZM, LiH, SunH, HoK. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev, 54:561–587. 2002.
RabbaniZN, SpasojevicI, ZhangX, MoellerBJ, HaberleS, Vasquez-VivarJ, DewhirstMW, VujaskovicZ, Batinic-HaberleI. Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP5+, via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med, 47:992–1004. 2009.
307.
RackhamO, NicholsSJ, LeedmanPJ, Berners-PriceSJ, FilipovskaA. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria. Biochem Pharmacol, 74:992–1002. 2007.
308.
Rademaker-LakhaiJM, van den BongardD, PluimD, BeijnenJH, SchellensJH. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res, 10:3717–3727. 2004.
309.
Ramirez-RamirezN, Mendoza-DiazG, Pedraza-ReyesM. Degradation of single stranded nucleic acids by the chemical nuclease activity of the metal complex [Cu(phen)(nal)]Bioinorg Chem Appl, 1:25–34. 2003.
310.
RauxE, SchubertHL, WarrenMJ. Biosynthesis of cobalamin (vitamin B12): a bacterial conundrum. Cell Mol Life Sci, 57:1880–1893. 2000.
311.
RayRS, GhoshB, RanaA, ChatterjeeM. Suppression of cell proliferation, induction of apoptosis and cell cycle arrest: chemopreventive activity of vanadium in vivo and in vitro. Int J Cancer, 120:13–23. 2007.
312.
RaynaudFI, MistryP, DonaghueA, PoonGK, KellandLR, BarnardCF, MurrerBA, HarrapKR. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol, 38:155–162. 1996.
313.
RaynaudFI, OdellDE, KellandLR. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. Br J Cancer, 74:380–386. 1996.
314.
RebillardA, Jouan-LanhouetS, JouanE, LegembreP, PizonM, SergentO, GilotD, TekpliX, Lagadic-GossmannD, Dimanche-BoitrelMT. Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. Eur J Cancer, 46:1445–1455. 2010.
315.
RebillardA, Lagadic-GossmannD, Dimanche-BoitrelMT. Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem, 15:2656–2663. 2008.
316.
ReboucheCJ. Ascorbic acid and carnitine biosynthesis. Am J Clin Nutr, 54:1147S–1152S. 1991.
317.
ReisnerE, ArionVB, Guedes da SilvaMFC, LichteneckerR, EichingerA, KepplerBK, KukushkinVY, PombeiroAJL. Tuning of redox potentials for the design of ruthenium anticancer drugs—an electrochemical study of [trans-RuCl4L(DMSO)]- and [trans-RuCl4L2]- complexes, where L=imidazole, 1,2,4-triazole, indazole. Inorg Chem, 43:7083–7093. 2004.
RheeSG, ChaeHZ, KimK. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med, 38:1543–1552. 2005.
320.
RigobelloMP, FoldaA, DaniB, MenaboR, ScutariG, BindoliA. Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells. Eur J Pharmacol, 582:26–34. 2008.
RonconiL, MarzanoC, ZanelloP, CorsiniM, MioloG, MaccaC, TrevisanA, FregonaD. Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties. J Med Chem, 49:1648–1657. 2006.
323.
RosenbergB, VanCampL, TroskoJE, MansourVH. Platinum compounds: a new class of potent antitumour agents. Nature, 222:385–386. 1969.
324.
RosenthalDI, NurenbergP, BecerraCR, FrenkelEP, CarboneDP, LumBL, MillerR, EngelJ, YoungS, MilesD, RenschlerMF. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res, 5:739–745. 1999.
325.
Ruiz-SanchezP, KonigC, FerrariS, AlbertoR. Vitamin B(12) as a carrier for targeted platinum delivery: in vitro cytotoxicity and mechanistic studies. J Biol Inorg Chem, 16:33–44. 2011.
326.
SalveminiD, DoyleTM, CuzzocreaS. Superoxide, peroxynitrite and oxidative/nitrative stress in inflammation. Biochem Soc Trans, 34:965–970. 2006.
327.
SamimiG, KishimotoS, ManorekG, BreauxJK, HowellSB. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother Pharmacol, 59:301–312. 2007.
SanchezY, AmranD, FernandezC, de BlasE, AllerP. Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK)Int J Cancer, 123:1205–1214. 2008.
330.
SantosNA, BezerraCS, MartinsNM, CurtiC, BianchiML, SantosAC. Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol, 61:145–155. 2008.
331.
SaryanLA, AnkelE, KrishnamurtiC, PeteringDH, ElfordH. Comparative cytotoxic and biochemical effects of ligands and metal complexes of alpha-N-heterocyclic carboxaldehyde thiosemicarbazones. J Med Chem, 22:1218–1221. 1979.
332.
SaryanLA, MailerK, KrishnamurtiC, AntholineW, PeteringDH. Interaction of 2-formylpyridine thiosemicarbazonato copper(II) with Ehrlich ascites tumor cells. Biochem Pharmacol, 30:1595–1604. 1981.
333.
SasadaT, NakamuraH, UedaS, SatoN, KitaokaY, GonY, TakabayashiA, SpyrouG, HolmgrenA, YodoiJ. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II)Free Radic Biol Med, 27:504–514. 1999.
334.
SavaG, BergamoA, ZorzetS, GavaB, CasarsaC, CocchiettoM, FurlaniA, ScarciaV, SerliB, IengoE, AlessioE, MestroniG. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur J Cancer, 38:427–435. 2002.
335.
SavaG, ZorzetS, MestroniG, ZassinovichG. Antineoplastic activity of planar rhodium(I) complexes in mice bearing Lewis lung carcinoma and P388 leukemia. Anticancer Res, 5:249–252. 1985.
336.
SchaferFQ, BuettnerGR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med, 30:1191–1212. 2001.
337.
SchilderRJ, LaCretaFP, PerezRP, JohnsonSW, BrennanJM, RogatkoA, NashS, McAleerC, HamiltonTC, RobyDet al.Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res, 54:709–717. 1994.
338.
SchlugaP, HartingerCG, EggerA, ReisnerE, GalanskiM, JakupecMA, KepplerBK. Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans, 14:1796–1802. 2006.
339.
Schuhmacher-WolzU, DieterHH, KleinD, SchneiderK. Oral exposure to inorganic arsenic: evaluation of its carcinogenic and non-carcinogenic effects. Crit Rev Toxicol, 39:271–298. 2009.
340.
ScrivensPJ, Alaoui-JamaliMA, GianniniG, WangT, LoignonM, BatistG, SandorVA. Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues. Mol Cancer Ther, 2:1053–1059. 2003.
341.
ShaoJ, ZhouB, ChuB, YenY. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets, 6:409–431. 2006.
342.
ShaoJ, ZhouB, Di BilioAJ, ZhuL, WangT, QiC, ShihJ, YenY. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther, 5:586–592. 2006.
ShenZX, ChenGQ, NiJH, LiXS, XiongSM, QiuQY, ZhuJ, TangW, SunGL, YangKQ, ChenY, ZhouL, FangZW, WangYT, MaJ, ZhangP, ZhangTD, ChenSJ, ChenZ, WangZY. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89:3354–3360. 1997.
345.
ShiTS, BerglundJ, EldingLI. Kinetics and mechanism for reduction of trans-dichlorotetracyanoplatinate(IV) by thioglycolic acid, L-cysteine, DL-penicillamine, and glutathione in aqueous solution. Inorg Chem, 35:3498–3503. 1996.
346.
ShiTS, BerglundJ, EldingLI. Reduction of trans-dichloro- and trans-dibromo-tetracyano-platinate(IV) by L-methionine. J Chem Soc Dalton Trans, 12:2073–2077. 1997.
347.
ShiX, DalalNS. Hydroxyl radical generation in the NADH/microsomal reduction of vanadate. Free Radic Res Commun, 17:369–376. 1992.
348.
ShiX, FlynnDC, LiuK, DalalN. Vanadium (IV) formation in the reduction of vanadate by glutathione reductase/NADPH and the role of molecular oxygen. Ann Clin Lab Sci, 27:422–427. 1997.
349.
ShiX, JiangH, MaoY, YeJ, SaffiottiU. Vanadium(IV)-mediated free radical generation and related 2′-deoxyguanosine hydroxylation and DNA damage. Toxicology, 106:27–38. 1996.
350.
ShiXL, DalalNS. Flavoenzymes reduce vanadium(V) and molecular oxygen and generate hydroxyl radical. Arch Biochem Biophys, 289:355–361. 1991.
351.
ShiY, AminK, SatoBG, SamuelssonSJ, SambucettiL, HaroonZA, LaderouteK, MurphyBJ. The metal-responsive transcription factor-1 protein is elevated in human tumors. Cancer Biol Ther, 9:469–476. 2010.
352.
ShimizuY, HendershotLM. Oxidative folding: cellular strategies for dealing with the resultant equimolar production of reactive oxygen species. Antioxid Redox Signal, 11:2317–2331. 2009.
353.
SigmanDS, GrahamDR, D'AuroraV, SternAM. Oxygen-dependent cleavage of DNA by the 1,10-phenanthroline. cuprous complex. Inhibition of Escherichia coli DNA polymerase I. J Biol Chem, 254:12269–12272. 1979.
354.
SigmanDS, MazumderA, PerrinDM. Chemical Nucleases. Chem Rev, 93:2295–2316. 1993.
355.
SinghS, VrishniS, SinghBK, RahmanI, KakkarP. Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic Res, 44:1267–1288. 2010.
356.
SmithPF, HokeGD, AlbertsDW, BugelskiPJ, LupoS, MirabelliCK, RushGF. Mechanism of toxicity of an experimental bidentate phosphine gold complexed antineoplastic agent in isolated rat hepatocytes. J Pharmacol Exp Ther, 249:944–50. 1989.
357.
SnyderRM, MirabelliCK, CrookeST. Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. Biochem Pharmacol, 35:923–932. 1986.
358.
SodhiA, GuptaP. Increased release of hydrogen peroxide (H2O2) and superoxide anion (O-2) by murine macrophages in vitro after cis-platin treatment. Int J Immunopharmacol, 8:709–714. 1986.
359.
SoignetSL, FrankelSR, DouerD, TallmanMS, KantarjianH, CallejaE, StoneRM, KalaycioM, ScheinbergDA, SteinherzP, SieversEL, CoutreS, DahlbergS, EllisonR, WarrellRPJr.United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol, 19:3852–3860. 2001.
360.
SoignetSL, MaslakP, WangZG, JhanwarS, CallejaE, DardashtiLJ, CorsoD, DeBlasioA, GabriloveJ, ScheinbergDA, PandolfiPP, WarrellRPJr.Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 339:1341–1348. 1998.
361.
SpasojevicI, ShengH, WarnerDS, Batinic-HaberleI. Metalloporphyrins are versatile and powerful therapeutics: biomimetics of SOD, peroxyredoxin, and cyt P450. 2nd World Conference on Magic Bullets (Ehrlich II), Nürnberg, Germany, 2008.
362.
SteinhoffD, MohrU. On the question of a carcinogenic action of cobalt-containing compounds. Exp Pathol, 41:169–174. 1991.
363.
StewartDJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol, 63:12–31. 2007.
364.
StordalB, PavlakisN, DaveyR. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev, 33:347–357. 2007.
365.
SulyokM, HannS, HartingerCG, KepplerBK, StingederG, KoellenspergerG. Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. Journal of Analytical Atomic Spectrometry, 20:856–863. 2005.
366.
SurowiakP, MaternaV, KaplenkoI, SpaczynskiM, DietelM, LageH, ZabelM. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch, 447:626–633. 2005.
367.
SweeneyCJ, TakimotoC, WoodL, PorterJM, TracewellWG, DarwishM, D'AndreaDM, RemickSC. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol, 66:345–356. 2010.
368.
Tajmir-RiahiHA. Vitamin C interaction with cobalt-ammine cations. Synthesis, spectroscopic and structural characterization of cobalt-pentammine and cobalt-tetrammine sugar complexes containing L-ascorbate anion. Biophys Chem, 25:37–41. 1986.
369.
TalbotS, NelsonR, SelfWT. Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia. Br J Pharmacol, 154:940–948. 2008.
370.
TapioS, GroscheB. Arsenic in the aetiology of cancer. Mutat Res, 612:215–246. 2006.
371.
TesniereA, SchlemmerF, BoigeV, KeppO, MartinsI, GhiringhelliF, AymericL, MichaudM, ApetohL, BaraultL, MendiboureJ, PignonJP, JoosteV, van EndertP, DucreuxM, ZitvogelL, PiardF, KroemerG. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene, 29:482–491. 2010.
372.
TheilEC. Coordinating responses to iron and oxygen stress with DNA and mRNA promoters: the ferritin story. Biometals, 20:513–521. 2007.
ThompsonDC, VaismanA, SakataMK, WyrickSD, HolbrookDJ, ChaneySG. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat. Cancer Chemother Pharmacol, 36:439–447. 1995.
375.
TianC, GaoP, ZhengY, YueW, WangX, JinH, ChenQ. Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG2) to arsenic trioxide-induced cell death. Cell Res, 18:458–471. 2008.
376.
TimerbaevAR, FoteevaLS, RudnevAV, AbramskiJK, Polec-PawlakK, HartingerCG, JaroszM, KepplerBK. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE. Electrophoresis, 28:2235–2240. 2007.
377.
TimerbaevAR, HartingerCG, AleksenkoSS, KepplerBK. Interactions of Antitumor Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical Methodology. Chem Rev, 106:2224–2248. 2006.
378.
TonissenKF, Di TrapaniG. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res, 53:87–103. 2009.
379.
TouyzRM, SchiffrinEL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol, 122:339–352. 2004.
380.
TownsendDM, ManevichY, HeL, HutchensS, PazolesCJ, TewKD. Novel role for glutathione S-transferase pi. Regulator of protein S-glutathionylation following oxidative and nitrosative stress. J Biol Chem, 284:436–445. 2009.
381.
TrachoothamD, AlexandreJ, HuangP. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?Nat Rev Drug Discov, 8:579–591. 2009.
382.
TraskC, SilverstoneA, AshCM, EarlH, IrwinC, BakkerA, TobiasJS, SouhamiRL. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. J Clin Oncol, 9:1131–1137. 1991.
383.
TrigonaWL, MullarkyIK, CaoY, SordilloLM. Thioredoxin reductase regulates the induction of haem oxygenase-1 expression in aortic endothelial cells. Biochem J, 394:207–216. 2006.
384.
TsangSY, TamSC, BremnerI, BurkittMJ. Research communication copper-1,10-phenanthroline induces internucleosomal DNA fragmentation in HepG2 cells, resulting from direct oxidation by the hydroxyl radical. Biochem J, 317:13–16. 1996.
385.
TseHM, MiltonMJ, PiganelliJD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radical Biology and Medicine, 36:233–247. 2004.
386.
TsengCH. Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 25:1–22. 2007.
387.
TsimberidouAM, CamachoLH, VerstovsekS, NgC, HongDS, UeharaCK, GutierrezC, DaringS, StevensJ, KomarnitskyPB, SchwartzB, KurzrockR. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res, 15:4769–4776. 2009.
388.
ValkoM, RhodesCJ, MoncolJ, IzakovicM, MazurM. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact, 160:1–40. 2006.
389.
VergaraE, CasiniA, SorrentinoF, ZavaO, CerradaE, RigobelloMP, BindoliA, LagunaM, DysonPJ. Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands. ChemMedChem, 5:96–102. 2010.
390.
VilleneuveNF, LauA, ZhangDD. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal, 13:1699–1712. 2010.
391.
Vol'pinME, LevitinI, OsinskySP. pH-dependent organocobalt sources for active radical species: a new type of anticancer agents. Met Ions Biol Syst, 36:485–519. 1999.
392.
VolckovaE, WeaverE, BoseRN. Insight into the reactive form of the anticancer agent iproplatin. Eur J Med Chem, 43:1081–1084. 2008.
393.
WangF, XuJ, HabtemariamA, BellaJ, SadlerPJ. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate. J Am Chem Soc, 127:17734–17743. 2005.
394.
WangT, ZhangX, LiJJ. The role of NF-kappaB in the regulation of cell stress responses. Int Immunopharmacol, 2:1509–1520. 2002.
395.
WangY, HeQY, SunRW, CheCM, ChiuJF. GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res, 65:11553–11564. 2005.
396.
WardmanP, CandeiasLP. Fenton chemistry: an introduction. Radiat Res, 145:523–531. 1996.
397.
WareDC, BrothersPJ, ClarkGR, DennyWA, PalmerBD, WilsonWR. Synthesis, structures and hypoxia-selective cytotoxicity of cobalt(III) complexes containing tridentate amine and nitrogen mustard ligands. Dalton Trans, 6:925–932. 2000.
398.
WareDC, PalmerBD, WilsonWR, DennyWA. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J Med Chem, 36:1839–1846. 1993.
399.
WareDC, PalmerHR, BrothersPJ, RickardCE, WilsonWR, DennyWA. Bis-tropolonato derivatives of cobalt(III) complexes of bidentate aliphatic nitrogen mustards as potential hypoxia-selective cytotoxins. J Inorg Biochem, 68:215–224. 1997.
400.
WareDC, PalmerHR, PruijnFB, AndersonRF, BrothersPJ, DennyWA, WilsonWR. Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins. Anticancer Drug Des, 13:81–103. 1998.
401.
WatersSB, DevesaV, Del RazoLM, StybloM, ThomasDJ. Endogenous reductants support the catalytic function of recombinant rat cyt19, an arsenic methyltransferase. Chem Res Toxicol, 17:404–409. 2004.
402.
WeaverEL, BoseRN. Platinum(II) catalysis and radical intervention in reductions of platinum(IV) antitumor drugs by ascorbic acid. J Inorg Biochem, 95:231–239. 2003.
403.
WeissbachH, ResnickL, BrotN. Methionine sulfoxide reductases: history and cellular role in protecting against oxidative damage. Biochim Biophys Acta, 1703:203–212. 2005.
404.
WellsWW, RocquePA, XuDP, YangY, DeitsTL. Interactions of platinum complexes with thioltransferase(glutaredoxin), in vitro. Biochem Biophys Res Commun, 180:735–741. 1991.
405.
WitteAB, AnestalK, JerremalmE, EhrssonH, ArnerES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med, 39:696–703. 2005.
406.
WolfCR, HaywardIP, LawrieSS, BucktonK, McIntyreMA, AdamsDJ, LewisAD, ScottAR, SmythJF. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer, 39:695–702. 1987.
407.
WondrakGT. Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities. Antioxid Redox Signal, 11:3013–3069. 2009.
408.
WoynarowskiJM, ChapmanWG, NapierC, HerzigMC, JuniewiczP. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol, 54:770–777. 1998.
409.
WuJ, HendersonC, FeunL, Van VeldhuizenP, GoldP, ZhengH, RyanT, BlaszkowskyLS, ChenH, CostaM, RosenzweigB, NierodzikM, HochsterH, MuggiaF, AbbadessaG, LewisJ, ZhuAX. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs, 28:670–676. 2010.
410.
WuXX, OgawaO, KakehiY. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Int J Oncol, 24:1489–1497. 2004.
411.
YamamotoN, DanosS, BonnitchaPD, FailesTW, NewEJ, HambleyTW. Cellular uptake and distribution of cobalt complexes of fluorescent ligands. J Biol Inorg Chem, 13:861–871. 2008.
412.
YanH, ParsonsDW, JinG, McLendonR, RasheedBA, YuanW, KosI, Batinic-HaberleI, JonesS, RigginsGJ, FriedmanH, FriedmanA, ReardonD, HerndonJ, KinzlerKW, VelculescuVE, VogelsteinB, BignerDD. IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360:765–773. 2009.
YangCH, KuoML, ChenJC, ChenYC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer, 81:796–799. 1999.
415.
YangM, KroftSH, ChitambarCR. Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther, 6:633–643. 2007.
416.
YangX, Chen-BarrettY, ArosioP, ChasteenND. Reaction paths of iron oxidation and hydrolysis in horse spleen and recombinant human ferritins. Biochemistry, 37:9743–9750. 1998.
417.
YangyuoruPM, WebbJW, ShawCF3rd. Glutathionato-S-Gold(III) complexes formed as intermediates in the reduction of auricyanide by glutathione. J Inorg Biochem, 102:584–593. 2008.
418.
YeX, FelsD, DedeugdC, DewhirstMW, LeongK, Batinic-HaberleI. Antioxidants and Novel Therapeutics. Free Radical Biology and Medicine, 47:S137. 2009.
419.
YiJ, GaoF, ShiG, LiH, ShiX, TangX. Apoptosis susceptibility of tumor cells to arsenic trioxide and the inherent cellular level of reactive oxygen species. Chin Med J (Engl), 115:603–606. 2002.
420.
YounHS, LeeJY, SaitohSI, MiyakeK, HwangDH. Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. Biochem Biophys Res Commun, 350:866–871. 2006.
421.
YuY, KalinowskiDS, KovacevicZ, SiafakasAR, JanssonPJ, StefaniC, LovejoyDB, SharpePC, BernhardtPV, RichardsonDR. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem, 52:5271–5294. 2009.
422.
ZakharyanRA, Sampayo-ReyesA, HealySM, TsaprailisG, BoardPG, LieblerDC, AposhianHV. Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem Res Toxicol, 14:1051–1057. 2001.
423.
ZakharyanRA, TsaprailisG, ChowdhuryUK, HernandezA, AposhianHV. Interactions of sodium selenite, glutathione, arsenic species, and omega class human glutathione transferase. Chem Res Toxicol, 18:1287–1295. 2005.
424.
ZassinovichG, MestroniG, CamusA. Diolefinic complexes of rhodium(I) and iridium(I) with nitrogen-containing ligands. J Organomet Chem, 91:379–88. 1975.
425.
ZelenkoO, GallagherJ, XuY, SigmanDS. Chemical nuclease activity of 1,10-phenanthroline-copper. Isotopic probes of mechanism. Inorg Chem, 37:2198–2204. 1998.
426.
ZellerWJ, FruhaufS, ChenG, KepplerBK, FreiE, KaufmannM. Chemoresistance in rat ovarian tumours. Eur J Cancer, 27:62–67. 1991.
427.
ZhangN, WuZM, McGowanE, ShiJ, HongZB, DingCW, XiaP, DiW. Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: Therapeutic potential for ovarian cancer. Cancer Sci, 100:2459–2464. 2009.
428.
ZhangX, FrezzaM, MilacicV, RonconiL, FanYH, BiCF, FregonaD, DouQP. Inhibition of Tumor Proteasome Activity by Gold-Dithiocarbamato Complexes via Both Redox-Dependent and -Independent Processes. J Cell Biochem, 109:162–172. 2010.
429.
ZhangXW, YanXJ, ZhouZR, YangFF, WuZY, SunHB, LiangWX, SongAX, Lallemand-BreitenbachV, JeanneM, ZhangQY, YangHY, HuangQH, ZhouGB, TongJH, ZhangY, WuJH, HuHY, de TheH, ChenSJ, ChenZ. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 328:240–243. 2010.
